Prelude Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-62,847
| Closed | -$1.17M | – | 1480 |
|
|
2023
Q3 | $1.17M | Buy |
+62,847
| New | +$711K | 0.08% | 278 |
|
|
2021
Q1 | – | Sell |
-13,830
| Closed | -$386K | – | 1894 |
|
|
2020
Q4 | $342K | Buy |
+13,830
| New | +$458K | 0.01% | 859 |
|
|
2019
Q4 | – | Sell |
-151
| Closed | -$10K | – | 2340 |
|
|
2019
Q3 | $10K | Sell |
151
-3
| -2% | -$201 | ﹤0.01% | 1500 |
|
|
2019
Q2 | $12K | Sell |
154
-20
| -11% | -$1.79K | ﹤0.01% | 1368 |
|
|
2019
Q1 | $19K | Buy |
174
+101
| +138% | +$11K | ﹤0.01% | 1327 |
|
|
2018
Q4 | $7K | Hold |
73
| – | – | ﹤0.01% | 1492 |
|
|
2018
Q3 | $9K | Sell |
73
-13,070
| -99% | -$1.38M | ﹤0.01% | 1494 |
|
|
2018
Q2 | $1.1M | Buy |
+13,143
| New | +$962K | 0.07% | 305 |
|
|
2017
Q4 | – | Sell |
-1,754
| Closed | -$102K | – | 1805 |
|
|
2017
Q3 | $102K | Sell |
1,754
-15,813
| -90% | -$1.7M | 0.01% | 872 |
|
|
2017
Q2 | $2.13M | Buy |
17,567
+16,107
| +1,103% | +$1.87M | 0.2% | 109 |
|
|
2017
Q1 | $165K | Buy |
+1,460
| New | +$170K | 0.02% | 627 |
|
Prelude Capital Management's ICPT Position: Q4 2023 in Review
Prelude Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 62,847 shares — an estimated $1.17M sold.
Prelude Capital Management first reported a position in ICPT in Q1 2017 and held it in 11 quarters. The position peaked at $2.13M in Q2 2017. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Prelude Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Prelude Capital Management sold 62,847 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $1.17M.
- Prelude Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2017 and held it in 11 quarters.
- Prelude Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $2.13M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.